The Technical Analyst
Kyverna Therapeutics, [KYTX]
Exchange: Nasdaq Sector: Healthcare Industry: Biotechnology
Kyverna Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-8.46% $13.96
America/New_York / 6 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 601.89 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Jun 25, 2024 |
| SharesOutstanding: | 43.12 mill |
| Avg Daily Volume: | 0.411 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.27 - 15.65 ( +/- 12.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-12 | Gilead Sciences, Inc. | Buy | 910 000 | Common Stock |
| 2024-02-12 | Gilead Sciences, Inc. | Buy | 3 216 119 | Common Stock |
| 2024-02-12 | Gilead Sciences, Inc. | Sell | 6 890 744 | Series A-2 Convertible Preferred Stock |
| 2024-02-12 | Gilead Sciences, Inc. | Sell | 7 746 139 | Series B Convertible Preferred Stock |
| 2024-02-07 | Clark Ian T | Sell | 38 736 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -64.72 |
| Last 14 transactions |
| Buy: 4 126 119 | Sell: 19 332 379 |
Forecast:
16:00 - $13.96
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.96
Forecast 2: 16:00 - $13.96
Forecast 3: 16:00 - $13.96
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.96 (-8.46% ) |
| Volume | 0.238 mill |
| Avg. Vol. | 0.411 mill |
| % of Avg. Vol | 58.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KYTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 9 - 10:41 | buy | $30.00 | N/A | Active |
|---|
KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 17:01:00 - Press Release
Kyverna Therapeutics To Attend The 2024 American Academy Of Neurology (aan) Annual Meeting In Denver, Co, With Data On Kyv-101 In The Treatment Of Patients With Neurological Autoimmune Diseases
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and lambert-eaton myasthenic syndrome with autologous cd19-targeted car-t cells kyverna to host a conference call on april 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis emeryville, calif. , april 11, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the american academy of neurology to be held in denver, colorado, starting on april 13.
2024-03-29 14:59:00 - Press Release
First-in-disease Use Of Kyverna Therapeutics' Kyv-101 In Patients With Progressive Multiple Sclerosis Published In Med
Two patients were treated with kyv-101, a fully human anti-cd19 car t-cell product candidate, in germany as part of a named patient program after failure to respond to conventional therapies the treatment resulted in an acceptable safety profile, with no observed clinical signs of early neurotoxicity, warranting larger clinical studies in subjects with multiple sclerosis emeryville, calif. , march 29, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announces today the publication in med1, of a report describing the first use of kyv-101, a fully human anti-cd19 chimeric antigen receptor (car) t-cell product candidate, in two patients suffering from progressive multiple sclerosis (ms) as part of a named patient program for critically ill patients after both patients failed to respond to conventional therapies.
2024-03-26 16:05:00 - Press Release
Kyverna Therapeutics Provides Business Update And Reports Full Year 2023 Financial Results
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 emeryville, calif. , march 26, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the full year ended december 31, 2023.
2024-03-07 19:26:00 - Press Release
Kyverna Therapeutics And Stanford University Agree To Evaluate Kyv-101 In Patients With Non-relapsing And Progressive Forms Of Multiple Sclerosis
The investigator-initiated trial will assess the safety, tolerability, and clinical activity of kyv-101, a fully human anti cd19 car t-cell therapy in up to 12 study participants the clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between kyverna and stanford university the agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of kyv-101 in multiple diseases and locations around the world emeryville, calif. , march 7, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with stanford university to allow the use of kyv-101, an investigational, anti-cd19 car t-cell therapy in an open label, phase 1 investigator-initiated trial (iit) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis.
2024-02-12 16:39:00 - Press Release
Kyverna Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Emeryville, calif. , feb. 12, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the closing of its upsized initial public offering of 16,675,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,175,000 additional shares, at an initial public offering price of $22.00 per share.
Latest News
2024-02-10 04:27:00 - Seeking Alpha
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week
2024-02-08 13:43:14 - Reuters
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.
2024-02-07 23:05:40 - Reuters
Kyverna Therapeutics to raise $319 million in upsized IPO
Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).
2024-02-04 06:16:00 - Seeking Alpha
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of the range to raise $129 million at a $456 million market cap.
2024-02-01 07:09:46 - Reuters
Kyverna Therapeutics targets up to $711 mln valuation in US IPO
Biotechnology company Kyverna Therapeutics said on Thursday it was aiming for a market valuation of up to $711 million in its U.S. initial public offering (IPO).